{"nctId":"NCT04721912","briefTitle":"Group B Streptococcus Response After Probiotic Exposure","startDateStruct":{"date":"2020-12-24","type":"ACTUAL"},"conditions":["Group B Strep Infection"],"count":68,"armGroups":[{"label":"Standard of Care","type":"NO_INTERVENTION","interventionNames":[]},{"label":"Probiotic Dietary Supplement","type":"EXPERIMENTAL","interventionNames":["Drug: Probiotic dietary supplement"]}],"interventions":[{"name":"Probiotic dietary supplement","otherNames":["Florajen Digestion™"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n• Healthy adult (≥ 18 years of age) pregnant women who are 36 - 37 6/7 weeks gestation at enrollment \\[calculated from the first day of Last Normal Menstrual Period (LNMP) and/or ultrasound (US)\\]\n\nGroup B Streptococcus Positive at 36 weeks gestation with:\n\n* No obstetric complication requiring delivery prior to 39 weeks (hypertensive disorder diagnosed prior to enrollment, gestational diabetes, multiple gestation)\n* No fetal complication (e.g., birth defect, intrauterine growth restriction)\n* No medical complication (e.g., chronic hypertension, preexisting diabetes mellitus)\n* Who do not currently ingest an over the counter probiotic supplement (not including yogurt)\n* Who can both speak and read English or Spanish\n* Pregnant women who regularly attend UNM prenatal clinics for their prenatal care (\"regularly attend\" will be defined as starting prenatal care prior to 20 weeks gestation and missing no more than one prenatal appointment during this pregnancy)\n* No hypersensitivity reaction to β-lactam antibiotics\n\nExclusion Criteria:\n\n* Those less than 18 years of age\n* Non-pregnant women\n* Later in pregnancy than 38 weeks gestation at enrollment \\[per LNMP and/or US\\]\n* Those with an obstetric, fetal or medical complication of pregnancy\n* Group B Streptococcus negative at 36 weeks gestation. Those ineligible for testing at 36 weeks gestation (history of GBS bacteriuria during the current pregnancy or have previously given birth to a GBS affected child.) We will not exclude those with bacteriuria other than GBS, and we will not exclude women who have taken an antibiotic during pregnancy, but we will track this as it is addressed in the Questionnaire for Women.\n* Women who are currently ingesting an over the counter probiotic supplement (except for yogurt)\n* Women who do not have electricity in the home.\n* Women who are planning an elective repeat cesarean birth\n* Women who do not speak and read English or Spanish\n* Women with a history of missing one or more scheduled prenatal visit during this pregnancy\n* Hypersensitivity reaction to β-lactam antibiotics","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"GBS Culture Result (Positive Versus Negative)","description":"Qualitative GBS colonization (positive versus negative)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Probiotic Pill Count to Measure Intervention Adherence","description":"Intervention adherence by pill count for probiotic participants","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"14","spread":"7.87"}]}]}]},{"type":"SECONDARY","title":"Antepartum Gastrointestinal Symptom Assessment (AP-GI-SA) Score","description":"Maternal gastrointestinal (GI) symptoms based on AP-GI-SA score: lowest score 10, highest score 50 (high score means more symptoms = worse outcome)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":"3.3"},{"groupId":"OG001","value":"15.0","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":"4.8"},{"groupId":"OG001","value":"13.5","spread":"4.7"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Report Adverse Events","description":"Maternal adverse events by organ system and severity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Report Adverse Events in Their Infant","description":"Infant adverse events by organ system and severity","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":[]}}}